Nasal spray aims to fight COVID-19, but trial halted early
NCT ID NCT05541510
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a nasal spray called AD17002 in 180 adults with mild to moderate COVID-19. Participants received either a low dose, high dose, or placebo spray alongside standard care. The goal was to see if the spray speeds up recovery and improves symptoms. However, the trial was terminated early, so we have limited data on its effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AD17002 (LTh[αK]) intranasal spray
What this could lead to
If successful, this could provide a new treatment option for mild to moderate COVID-19 that boosts nasal immunity.
What could go wrong
The trial was terminated early, so results are limited. It is unclear if the treatment works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
RSA UGM
Yogyakarta, Special Region of Yogyakarta, 55281, Indonesia
-
RSDC Wisma Atlit
Kota Jkt Utara, DKI Jakarta, 14360, Indonesia
-
RSPI Sulianti Saroso
Kota Jkt Utara, DKI Jakarta, 14340, Indonesia